Summary: Download this webinar to hear various approaches to generate batch comparability results for a biosimilar glycoprotein and vaccine candidate

Catalent offers a comprehensive suite of analytical services for traditional biologics and advanced therapies such as antibody-drug conjugates (ADCs), cell and gene therapies, and mRNA vaccines, including drug substance, drug product and intermediates, at our biologics analytical sites in the United States.

Summary: The FDA requires that host cell proteins (HCPs) be reduced to low levels because they can affect the safety and efficacy of a drug. Pharmaceutical Technology recently spoke with...

Summary: Bioassays and binding assays play a critical role in ensuring product quality, safety and efficacy.

Summary: Analytical testing for biologics is evolving rapidly as new protocols become available and companies seek to expedite current methodologies.

Summary: The FDA requires that host cell proteins (HCPs) be reduced to low levels because they can affect the safety and efficacy of a drug. Pharmaceutical Technology recently spoke...

Summary: Download the infographic to learn more about the latest cell-based bioassays and binding assays with an emphasis on their applications in the industry.

Summary: Patient centricity has always been at the heart of the pharmaceutical industry. With rising costs of drugs and healthcare, there has been...

Summary: In this article, Luke Deters, Director of Biologics, discusses an appropriate method for quantification and characterization of polysorbate-80 (PS-80), a commonly-used, but highly-heterogenous, surfactant...

Summary: Our regulatory team completes over 150 agency submissions each year, supporting all stages of the product lifecycle. We assign a dedicated regulatory professional to each of our clients...